Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587003 | 0.97 | CYP2C19 (0.65) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL2763827 | 0.96 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL14478600 | 0.95 | LMNA (0.63) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL1742986 | 0.94 | LMNA (0.59) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL3783951 | 0.94 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL1742158 | 0.93 | LMNA (0.58) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19645487 | 0.93 | LMNA (0.61) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8583797 | 0.93 | CYP2C19 (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261514 | 0.92 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8588233 | 0.92 | CYP2C19 (0.59) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163275-A1 | FLAME-RESISTANT THREE-DIMENSIONAL PRINTED ARTICLES | PERIDOT PRINT LLC | 2025-05-22 | — | — | US | claimed |
| EP-4482902-A1 | FLAME-RESISTANT THREE-DIMENSIONAL PRINTED ARTICLES | Hewlett-Packard Development Company, L.P. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023163710-A1 | FLAME-RESISTANT THREE-DIMENSIONAL PRINTED ARTICLES | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230042522-A1 | INKJET COMPOSITION | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2023-02-09 | — | — | US | claimed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | claimed |
| EP-2178568-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2014-07-02 | — | — | EP | claimed |
| EP-2286887-B1 | Endotoxin removal in contrast media | GE HEALTHCARE AS (NO) | 2012-01-25 | — | — | EP | claimed |
| EP-2286887-A1 | Endotoxin removal in contrast media | GE Healthcare AS (NO) | 2011-02-23 | — | — | EP | claimed |
| US-20110017673-A1 | ENDOTOXIN REMOVAL IN CONTRAST MEDIA | GE HEALTHCARE AS (NO) | 2011-01-27 | — | — | US | claimed |
| WO-2010079201-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2010-07-15 | — | — | WO | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250263546-A1 | ENDOLUMINAL DEVICE AND POLYMER | ENDOLOGIX LLC | 2025-08-21 | — | — | US | disclosed |
| EP-3700465-B1 | ENDOLUMINAL DEVICE AND POLYMER | ENDOLOGIX LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12240973-B2 | Endoluminal device and polymer | ENDOLOGIX LLC (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4482902-A1 | FLAME-RESISTANT THREE-DIMENSIONAL PRINTED ARTICLES | Hewlett-Packard Development Company, L.P. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20100322868-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-23 | — | — | US | disclosed |
| US-20100322868-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-23 | — | — | US | disclosed |
| WO-2010079201-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178568-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009008734-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100322868-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.